Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3815 | Supraflex Cruz 60 Micron Wiki | 0.50 |
| drug436 | BAT2020 Wiki | 0.50 |
| drug4132 | Ultimaster Tansei 80 Micron Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001997 | Bronchopulmonary Dysplasia NIH | 0.50 |
| D008595 | Menorrhagia NIH | 0.50 |
| D006929 | Hyperaldosteronism NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013226 | Status Epilepticus NIH | 0.50 |
| D002543 | Cerebral Hemorrhage NIH | 0.50 |
| D054559 | Hyperphosphatemia NIH | 0.50 |
| D004314 | Down Syndrome NIH | 0.50 |
| D013345 | Subarachnoid Hemorrhage NIH | 0.50 |
| D000309 | Adrenal Insufficiency NIH | 0.50 |
| D007008 | Hypokalemia NIH | 0.50 |
| D014552 | Urinary Tract Infections NIH | 0.35 |
| D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.29 |
| D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.25 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.17 |
| D001930 | Brain Injuries, NIH | 0.14 |
| D006331 | Heart Diseases NIH | 0.13 |
| D020141 | Hemostatic Disorders NIH | 0.13 |
| D001778 | Blood Coagulation Disorders NIH | 0.13 |
| D020521 | Stroke NIH | 0.13 |
| D006973 | Hypertension NIH | 0.10 |
| D014947 | Wounds and Injuries NIH | 0.08 |
| D004194 | Disease NIH | 0.08 |
| D013577 | Syndrome NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002905 | Hyperphosphatemia HPO | 0.50 |
| HP:0002900 | Hypokalemia HPO | 0.50 |
| HP:0002133 | Status epilepticus HPO | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000846 | Adrenal insufficiency HPO | 0.50 |
| HP:0002138 | Subarachnoid hemorrhage HPO | 0.50 |
| HP:0000132 | Menorrhagia HPO | 0.50 |
| HP:0001342 | Cerebral hemorrhage HPO | 0.50 |
| HP:0000859 | Hyperaldosteronism HPO | 0.50 |
| HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.25 |
| HP:0001928 | Abnormality of coagulation HPO | 0.13 |
| HP:0001297 | Stroke HPO | 0.13 |
| HP:0000822 | Hypertension HPO | 0.10 |
Navigate: Correlations HPO
There are 4 clinical trials
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
The main objectives are: - To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. - To identify variables associated to higher risk of bleeding.
Description: Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.
Measure: Bleeding events and complications Time: 30 daysA prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.
Description: Care treatment such as ventilator use, intubation, and/or tracheostomy
Measure: Limitations of patient care- Frequency of care not being provided Time: During In-hospital course, up to 1 monthThe study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
Description: The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.
Measure: Net Adverse Clinical Endpoints (NACE) Time: 1 yearDescription: Major adverse cardiac and cerebral events (MACCE) defined as a composite of cardiac death, myocardial infarction, target vessel revascularization and stroke
Measure: Major adverse cardiac and cerebral events (MACCE) Time: 1 yearDescription: Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events
Measure: Major or clinically relevant non-major bleeding (MCB) Time: 1 yearDescription: Target Lesion Failure (TLF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target lesion revascularization
Measure: Target Lesion Failure (TLF) Time: 1 yearDescription: Target Vessel Failure (TVF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target vessel revascularization
Measure: Target vessel failure (TVF) Time: 1 yearDescription: The composite endpoint of cardiovascular death, myocardial infarction and stroke
Measure: The composite of cardiovascular death, myocardial infarction and stroke Time: 1 yearDescription: The composite of cardiovascular death, myocardial infarction, stroke and major bleed according to BARC 3 and 5
Measure: The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5 Time: 1 yearDescription: Stent thrombosis according to the ARC definitions
Measure: Stent thrombosis Time: 1 yearDescription: Myocardial infarction.
Measure: Myocardial infarction Time: 1 yearDescription: Urgent target vessel revascularization.
Measure: Urgent target vessel revascularization Time: 1 yearDescription: Non-target vessel revascularization.
Measure: Non-target vessel revascularization Time: 1 yearDescription: Clinically indicated target vessel revascularization.
Measure: Clinically indicated target vessel revascularization Time: 1 yearDescription: Bleeding events according to the BARC, TIMI and GUSTO classification
Measure: Bleeding events Time: 1 yearDescription: Transfusion rates both in patients with and/or without clinically detected over bleeding
Measure: Transfusion rates Time: 1 yearDescription: Event rates according to the PRECISE-DAPT score
Measure: Event rates according to the PRECISE-DAPT Time: 1 yearDescription: Procedural success is defined as angiographic success with no in-hospital MACE, defined as death, MI with new Q-waves on electrocardiogram (ECG) or urgent target vessel revascularization (TVR) (including both repeat PCI and coronary artery bypass graft surgery (CABG)
Measure: Procedural success Time: At completion of the baseline PCIDescription: Device success (applying a lesion-level analysis)
Measure: Device success Time: At discharge of baseline hospitalisation, on average 3 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports